Table of Content

Title of Content	Pg. No
1.1.1 Etiology of obesity:	3
1.1.2 Epidemiology:	4
1.1.3 Pathophysiology:	5
1.2. Causes of Obesity	6
1.3. Psychosocial Factors contributing to Obesity	8
1.4. Remedies for obesity:	9
1.5. WHO Guidelines for Quality Assessment of Herbal Medicines	11
1.6. Quality of herbal products:	12
1.7. Parameters for Quality Control of Herbal Drugs and Herbal products	12
1.8. Standardization of Herbal Formulations	12
1.9. Medicinal Plants used for the treatment of obesity:	13
1.10 In silico Approach:	19
2.1. Current allopath treatment of obesity:	23
2.2 Current Herbal approach for the obesity:	23
2.3. Recent literature for Drug targets of obesity:	24
2.3.1 Pancreatic lipase enzyme inhibition:	25
2.3.2 Thermogenesis:	25
2.3.3 Lipid Metabolism:	25
2.3.4 Centrally acting mechanism:	25
2.4. Selection of herbs for formulation:	26
2.5. Achyranthes aspera:	28
2.5.1 PhytoConstituents of Achyranthus Aspera	28
2.5.2 Pharmacological properties:	29
2.6. Murraya Koenigii(L) Leaves:	29
2.6.1 PhytoConstituents:	29
2.6.2 Pharmacological properties:	30
2.7. Commiphora mukul gum (guggul):	30
2.7.1 Phytoconstituents:	31
2.7.2 Pharmacological Properties:	31
2.8. Garcinia indica fruit:	32
2.8.1 Phytoconstituents:	32
2.8.2 Pharmacological Properties:	32
2.9. Herbal Tablet formulation:	33
2.9.1 Methods Used for tablet formulation:	33
2.9.2 Excipients used for tablet formulation:	34
2.9.3 Evaluation Parameters of Tablets	34
2.10. Screening method for ant-obesity agents:	35

2.10.1 In-vitro Method: Pancreatic Lipase Inhibition Assay	35
2.10.2 In-vivo Animal models:	35
2.11. Analytical Method Development and Validation:	36
2.11.1 Analytical Method development:	36
2.11.2 Validation of Analytical Method:	37
2.12. Selection of Markers for AMD by HPLC and HPTLC:	38
2.13. In Silico Method for screening of marker compounds for obesity	39
4.1 Phytochemical Screening of plant extracts	53
4.1.1 Procurement of plant extracts:	53
4.1.2 Organoleptic evaluation:	53
4.1.3 Proximate Analysis of Each Plant Extracts:	53
4.1.3.1 Alkaloids:	53
4.1.3.2 Glycosides:	54
4.1.3.3 Carbohydrates:	55
4.1.3.4 Steroids:	55
4.1.3.5 Fats and oils:	55
4.1.3.6 Flavonoids:	55
4.1.3.7 Proteins:	56
4.1.3.8 Amino acids:	56
4.1.3.9 Tannins and Phenolic compounds	56
4.1.4 Thin Layer Chromatography of each Plant Extracts:	57
4.1.5 Microbial Analysis:	57
4.1.6 Determination of Moisture content:	57
4.1.7 Heavy metal Analysis:	58
4.1.8 Estimation of Secondary metabolites:	58
4.1.8.1 Determination of Total Phenolic content:	58
4.1.8.2 Determination of Total tannin content:	58
4.1.8.3 Determination of Total flavanoid content:	59
4.2 Formulation and Development:	59
4.2.1 Concentration of plant extract	59
4.2.2 Optimization of excipients was done by using response surface D optimal Factorial design	59
4.2.2.1 Variables for response	59
4.2.2.2 The obtained design matrix	60
4.2.2.3 Desired values of variables:	61
4.2.2.4 Results of Responses:	61
4.2.2.5 ANOVA Analysis for Disintegration time:	62
4.2.2.6 ANOVA analysis for Hardness:	65
4.2.3 Optimization of Formulation by Desirability Curve	67
4.2.4 Check Point Batch Analysis:	70
4.2.5 Optimized Parameters for the formulation:	71
4.2.6 Stability Study:	73
4.3 Analytical method development and Validation:	73

4.3.1 Analytical method development:	73
4.3.1.1 HPLC instrumentation:	73
4.3.1.2 Preparation of standard solution Gallic acid stock preparation:	75
4.3.1.3 Preparation of Sample Solution:	75
4.4Validation Parameters:	77
4.4.1Linearity:	77
4.4.3 Robustness	79
4.4.3 Limit of Detection (LOD):	79
4.4.4 Limit of Quantification:	79
4.4.5 Accuracy:	80
4.5 HPTLC Method Development and Validation:	80
Chemicals and Reagents:	80
4.5.1 Development of HPTLC Method:	80
4.5.1.1 HPTLC Instrumentation	80
4.5.1.2 Preparation of Standard solution	81
4.5.1.3 Preparation of Sample solution	81
4.5.1.4 Optimization of Mobile phase:	81
4.51.5 Validation of HPTLC method:	82
4.6. Anti-obesity evaluation of markers present in selected herbs using In Silico Approach.	85
4.6.1 Markers and selected class of drugs for evaluation.	85
4.6.2 Pancreatic α-Amylase (Inhibitory activity):	86
4.6.2.1 Molecular Docking Study:	86
4.6.3 Pancreatic Lipase:	87
4.6.3.1Molecular Docking Study	87
4.6.4 PPARs (peroxisome proliferator activated receptor) (PPARalpha):	88
4.6.4.1 Molecular Docking Study:	88
4.6.5 Leptin (LEP-R, LEP-Rb):	89
4.6.5.1Molecular Docking Study:	89
4.6.6 Cannabinoid receptor type 1(CB1):	90
4.6.6.1 Molecular Docking Study	90
4.6.7 HMG CoA Reductase:	91
5.1 Phytochemical screening and proximate analysis:	93
5.1.1 Phytochemical screening	93
5.1.2 Organoleptic evaluation:	94
5.1.3 Microbial Analysis:	94
5.1.4 Thin Layer Chromatography:	94
5.1.5 Determination of moisture content:	95
5.1.6 Determination of Heavy metals:	95
5.1.7 Detemination of secondary metabolites:	95
5.1.7.1 Determination of total phenolic content:	95
5.1.7.3 Determination of Total Flavanoid content:	97
Result of total Flavanoid content:	98

5.2 Tablet Formulation:	98
5.2.1 Preformulation data for tablet:	98
5.2.2 Development of Tablet Formulation:	99
5.2.3 Evaluation Parameters for tablet:	99
5.2.4 Stability Studies:	100
5.3 HPLC Analytical method development and validation:	100
5.3.1 HPLC Method development:	100
5.3.1.1 Method parameters:	100
5.3.1.2 Isoabsorptive point (Wavelength selection)	101
5.3.1.3 System Suitability Parameters:	101
5.3.2 HPLC Method Validation:	102
5.3.3 Quantification of Markers in developed polyherbal tablet	107
5.4 HPTLC Analytical method development and validation:	108
5.4.1 Method development:	108
5.4.2 HPTLC Method Validation:	110
5.4.3 Quantification of markers by HPTLC method	117
5.5 In silico evaluation results:	119
5.5.1 Pancreatic α-Amylase (Inhibitory activity):	119
5.5.2 Pancreatic Lipase:	121
5.5.3 PPARs (peroxisome proliferator activated receptor) (PPARalpha):	124
5.5.4 Leptin (LEP-R, LEP-Rb):	127
5.5.5 Cannabinoid receptor type 1(CB1):	130
5.5.6 HMG CoA Reductase:	132